-+ 0.00%
-+ 0.00%
-+ 0.00%

Anixa Biosciences Presents Phase 1 Breast Cancer Vaccine Data Showing All Major Endpoints Met

PUBT·11/05/2026 14:51:15
Listen to the news
Anixa Biosciences Presents Phase 1 Breast Cancer Vaccine Data Showing All Major Endpoints Met
  • Anixa Biosciences completed its breast cancer vaccine Phase 1 trial, meeting all major endpoints; Phase 2 enrollment is the next milestone.
  • Among 35 patients dosed, 74% showed a protocol-specified immune response; no safety concerns were reported.
  • Combining the vaccine with Keytruda produced no additional adverse effects, supporting combination use.
  • Lira-cel remains in Phase 1 for ovarian cancer, with periodic data releases tied to enrollment.
  • Cash and short-term investments totaled $14 million as of July 31, 2026, with no debt; last fiscal year's cash burn was $7 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.